Hyperglycemia during acute ischemic stroke has been associated with worse functional outcomes and hemorrhagic complications in the setting of thrombolysis.\(^1\)\(^2\) Whether hyperglycemia during acute ischemic stroke worsens functional outcomes or is merely a biomarker of stress or insulin resistance is unclear. Two randomized efficacy trials studied intensive hyperglycemia treatment during acute ischemic stroke.\(^3\)\(^4\) The first GIST-UK (United Kingdom Glucose Insulin in Stroke Trial) enrolled 933 patients, primarily without diabetes.\(^3\)
Intensive treatment consisted of intravenous insulin for 24 hours. During protocol treatment, the difference between the mean blood glucose (BG) concentrations in the 2 treatment groups was only 10 mg/dL. Functional outcomes at 90 days were not significantly different between the 2 treatment groups.

The second trial, SHINE (Stroke Hyperglycemia Insulin Network Effort), enrolled 1151 patients, primarily with diabetes. Intensive treatment consisted of intravenous insulin for up to 72 hours. During protocol treatment, the difference between the mean BG concentrations in the 2 treatment groups was 61 mg/dL. Functional outcomes at 90 days were not significantly different between the 2 treatment groups.

Although intensive insulin treatments during acute ischemic stroke with hyperglycemia did not improve functional outcomes in the 2 efficacy trials, there may be subgroups of acute stroke patients who might benefit from such intervention. Different glycemic measures may indicate different relationships between BG levels and acute ischemic brain injury. For example, clinically important differences in the effects of acute hyperglycemia may exist between patients with or without diabetes, those with greatest variations in BG levels during the acute stroke, or those with the highest levels of chronic hyperglycemia. In this analysis, we evaluated for associations between the SHINE randomized treatment group and the SHINE predefined 90-day functional outcome, within-patient subgroups defined by various glycemic parameters.

**METHODS**

**Study Population and Data Collection**

The data used to prepare this manuscript is available through the SHINE public use dataset in the National Institutes of Health (NIH) Data Repository (https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets). The design and primary outcome results of SHINE have been reported. Briefly, SHINE randomized 1:1 1151 patients with acute ischemic stroke and admission hyperglycemia (BG >110 mg/dL [6.1 mmol/L] if diabetes history was present or ≥150 mg/dL [8.3 mmol/L] if no diabetes history), within 12 hours from symptom onset to standard or intensive insulin treatment for up to 72 hours (Figure S1). Standard treatment consisted of subcutaneous regular insulin 4 times daily as needed according to a sliding-scale protocol. Intensive treatment consisted of intravenous insulin and subcutaneous rapid-acting meal insulin, and long-acting basal insulin. The BG targets were 80 to 180 mg/dL in the standard treatment group and 80 to 130 mg/dL in the intensive group. BG was usually monitored every 3 hours in the standard treatment group and every 1 hour in the intensive group. A computerized program calculated intravenous insulin doses and effectively and safely achieved the desired glucose target.

SHINE data collection included patient demographics, medical history, medication history, and glycated hemoglobin A1c (HbA1c) during hospitalization. Baseline stroke severity was defined according to the National Institutes of Health Stroke Scale (NIHSS) as mild (3–7), moderate (8–14), or severe (15–22). The primary favorable outcome was assessed in a double-blind fashion and defined as a 90-day modified Rankin Scale (mRS) score of 0, if the baseline NIHSS score was 3 to 7; an mRS score 0 to 1, if the baseline NIHSS was 8 to 14; and an mRS score 0 to 2, if the baseline NIHSS was 15 to 22. We used the same definition of favorable functional outcome in this analysis. SHINE was approved at each participating institution and all patients gave a valid informed consent.

**Patient Subgroups**

Based on previously reported glycemic parameters, we defined multiple subgroups for secondary analysis of efficacy of the SHINE trial intervention (Table). The patient subgroups included those without diabetes (true nondiabetic—no history of diabetes and HbA1c ≤6.5%), with history of diabetes, and those with undiagnosed diabetes (no history of diabetes and HbA1c >6.5%).

In addition, we examined the following continuous measurements: baseline (point of care) BG, glycemic gap, stress hyperglycemia ratio (SHR), and BG variability during SHINE protocol treatment. We used the glycemic gap definition of baseline BG concentration—expected average daily BG concentration. The expected average BG concentration was based on the HbA1c with the formula (28.7×HbA1c)–46.7. We used the SHR definition of baseline BG concentration/HbA1c. We used BG variability defined in each patient as the SD of all their BG measurements during the SHINE protocol treatment.

**Statistical Analysis**

Favorable functional outcomes by subgroup are reported as a proportion and compared between the 2 treatment groups using a relative risk and 2-sided 99% CI. Generalized linear models with a log link function were used to compare favorable outcomes between patient subgroups and between treatment groups within each patient subgroup. Relative risks are reported as unadjusted and adjusted by the primary prognostic variables used in the SHINE trial, baseline stroke severity according to the NIHSS, and thrombolysis use (yes/no). Linearity assumption for continuous variables was examined, and piecewise linear variables were created when indicated to account for nonlinear relationships between continuous covariates and outcomes. Any patients with missing data were excluded from the analysis. All analyses were performed using SAS 9.4 (SAS Institute, Inc Cary, NC). As prespecified in the SHINE statistical analysis plan for all exploratory subgroup analyses, a 2-sided significance level was 0.01.
RESULTS

Between April 2012 and August 2018, 1151 patients (mean age, 66 years [SD, 13.1 years]; 529 [46%] women, 920 [80%] with history of diabetes) were randomized. The primary outcome was not significantly different between the 2 treatment groups.4

Twenty-three percent of the patients had lacunar stroke, and 50% had mild stroke (NIHSS of 3–7) with an overall median NIHSS of 7. Reperfusion therapy was used in 68% of patients (63% received standard intravenous tissue-type plasminogen activator, 3% intraarterial therapies, and 13% mechanical thrombectomy). The median baseline glucose concentration was 188 mg/dL (interquartile range, 153–250) in the intensive treatment group and 187 mg/dL (interquartile range, 155–248) in the standard treatment group.

The Table shows the risks of favorable outcomes by diabetes patient subgroup. Likelihood for favorable outcome is lowest among patients with undiagnosed diabetes compared to patients with true nondiabetes (adjusted relative risk, 0.42 [99% CI, 0.19–0.94]). The Table also shows there is no relationship between the favorable outcome rate and baseline BG or any of the glycemic parameters.

Figure 1 shows the SHINE treatment effects within patient subgroups. The 99% CIs for all comparisons include the relative risk value of 1.00. No differences between SHINE treatment groups were identified among any of these patient subgroups at the nominal 0.01 level.

Nonlinear relationships between 3 continuous variables and favorable outcomes resulted in split continuous variables based on changes in slopes at the following points: baseline BG 238 mg/dL, glycemic gap 43.8 mg/dL, and stress hypoglycemia ratio 1.38 (Figure S2).

Figure 2 shows adjusted relative risks and 99% CIs for favorable outcomes at specific values for the 4 continuous variables analyzed. No differences between SHINE treatment groups were identified in any of these patient subgroups at the nominal 0.01 level.

DISCUSSION

In this secondary analysis of data from a randomized clinical acute stroke treatment trial, we evaluated the relationship between treatment and 90-day functional outcome in patient subgroups defined by glycemic parameters previously associated with functional outcome after stroke. Undiagnosed diabetes has been associated with worse functional outcomes after stroke.16 Our findings agree with this observation (Table). However, there is no clear SHINE treatment effect in this relatively small subgroup of patients with undiagnosed diabetes (Figure 1).

Several studies found glycemic variability and SHR to be independent risk factors of death in heterogeneous populations of critically ill patients.19,20 However, in acute stroke, the roles of these factors are not well defined.
Several studies showed an association with worse neurological outcome, which differs from our findings. This discrepancy might be due to differences in study design. The majority of prior studies were retrospective with variable definitions of SHR, lesser standardization of BG measurements, and without adjustment for the impact of stroke severity on functional outcome.

In one study of 666 patients with acute ischemic stroke undergoing intravenous thrombolysis, a higher SHR was independently associated with worse functional outcome adjusted for stroke severity. Two other studies found an association between higher SHR and worse clinical outcome in acute stroke patient treated with mechanical thrombectomy. However, Tziomalos et al reviewed 790 patients with acute ischemic stroke and found that the SHR was not associated with functional outcome after controlling for stroke severity, similar to our findings.

In a prospective registry of 1504 consecutive patients with diabetes and acute ischemic stroke higher BG concentrations were associated with worse functional outcomes. Patients in that study had relatively mild strokes, with average NIHSS from 2 to 4. In meta-analysis, admission hyperglycemia has also been associated with worse functional outcomes in stroke patients treated with mechanical thrombectomy. Thrombectomy retained its benefit during hyperglycemia, and the BG concentration was not associated with recanalization. However, in the SHINE trial, baseline BG concentration was not associated with functional outcome (Table), and there is no SHINE treatment effect along the range of baseline BG concentrations (Figure 2).

Poor glycemic control prestroke, as indicated by elevated serum HbA1c, has been associated with worse functional outcomes after ischemic stroke. In this study, an association between elevated HbA1c and reduced likelihood of favorable outcome was not detected (Table). Possibly, the SHINE trial patient selection criteria requiring prestroke functional independence created a selection bias that influenced our findings. In addition, there is no SHINE treatment effect within any of the HbA1c categories (Figure 1).

Greater BG fluctuations (variability) and admission glycemic gap during acute ischemic stroke have been associated with worse functional outcomes. In this study, an association between favorable outcome,
glycemic variability, and glycemic gap was not detected (Table). In addition, there was no SHINE treatment effect along the range of BG variabilities or admission glycemic gap (Figure 2).

A limitation of our findings is that this study was a post hoc analysis from the SHINE trial and as such was not powered to detect clinically important differences between treatment groups. In addition, the 0.01 threshold for statistical significance does not constitute an accurate correction for increased type I error. Nonetheless, our exploratory findings could help inform future studies.

**CONCLUSIONS**

In this exploratory subgroup analysis based on 6 glycemic parameters, intensive versus standard insulin treatment of hyperglycemia in patients with acute ischemic stroke, did not influence the 90-day functional outcome, nor did we identify associations between these parameters and the 90-day functional outcome.

**ARTICLE INFORMATION**

Received October 12, 2020; final revision received October 7, 2021; accepted November 12, 2021.

**Affiliations**

Department of Neurology, University of New Mexico, Albuquerque (M.T.T.). Department of Public Health Sciences, Medical University of South Carolina, Charleston (Q.P., V.L.D.). Department of Emergency Medicine, Temple University, Philadelphia, PA (N.G.). Department of Internal Medicine and Cincinnati VAMC, University of Cincinnati College of Medicine, OH (M.F.). Department of Emergency Medicine, University of Michigan, Ann Arbor (WM). Department of Neurology, University of Kentucky, Lexington (C.L.P.). Department of Neurology, Northwestern University, Chicago, IL (T.B.). Department of Neurology, Augusta University, GA (A.B.).

**Sources of Funding**

The SHINE trial (Stroke Hyperglycemia Insulin Network Effort) was funded by grants from the National Institutes of Health—National Institutes of Neurological Disorders and Stroke U01 NS069498, U01 NS056975, and U01 NS059041.

**Disclosures**

All the authors received National Institute of Neurological Disorders and Stroke (NINDS) funding for participation in the parent SHINE Trial (Stroke Hyperglycemia Insulin Network Effort). Dr Pettigrew received funding from Syneos Health LLC/Lumosa Therapeutics outside of the submitted work. Dr Gentile reports grants from National Institute of General Medical Sciences outside the submitted work.

---

**Figure 2.** Adjusted relative risks with 99% CIs for favorable functional outcomes by SHINE (Stroke Hyperglycemia Insulin Network Effort) treatment group at specific values for baseline blood glucose (BG), glycemic gap, stress hyperglycemia ratio, and BG variability.
REFERENCES

1. Ahmed N, Dávalos A, Eriksson N, Ford GA, Glaun J, Hennerici M, Mikulik R, Raste M, Lees KR, Lindsberg PJ, et al; SITS Investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: findings from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol. 2010;67:1123–1130. doi: 10.1001/archneurol.2010.210

2. Masnur S, Cox M, Bhatt DL, Smith EE, Elrod G, Fonarow GC, Schwamm L. Association of acute and chronic hyperglycemia with acute ischemic stroke outcomes post-thrombolysis: findings from get with the guidelines-stroke. J Am Heart Assoc. 2015;4:e002193. doi: 10.1161/JAHA.115.002193

3. Gray CS, Hildreth AJ, Sandeck PA, O’Connell JE, Johnston DE, Carllidge NE, Bamford JM, James OF, Alberti KG; GIST Triallists Collaboration. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397–406. doi: 10.1016/S1474-4422(07)70080-7

4. Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, Fanslier A, Van de Brinhorst K, Janis S, Durkalski VL; Neurological Emergencies Treatment Trials Network and the SHINE Investigators. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA. 2019;322:326–335. doi: 10.1001/jama.2019.9346

5. Hjalmarsson C, Manhem K, Bokemark L, Andersson B. The role of prestroke glycemict control on severity and outcome of acute ischemic stroke. Stroke Res Treat. 2012;2014:694569. doi: 10.1155/2014/694569

6. Yang CJ, Liao WI, Wang JC, Tsai CL, Lee JT, Peng GS, Lee CH, Hsu CW, Tsai SH. Usefulness of glycated hemoglobin A1c-based adjusted glycemic variables in diabetic patients presenting with acute ischemic stroke. Am J Emerg Med. 2017;35:1240–1246. doi: 10.1016/j.ajem.2017.03.049

7. Falcioglia M, Freyberg RW, Almenoff PL, D’Alessio DA, Render ML. Hyperglycaemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37:3001–3006. doi: 10.1097/CCM.0b013e3181e09837

8. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke and nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426–2432. doi: 10.1161/hs101.1096194

9. Nguyen JM, Cheong CWS, Leow AST, Wei YT, Thel JKK, Lee YS, Lia CH, Tan BYQ, Khoo CM, Sharma VK, et al. Stress hyperglycaemia is associated with poor functional outcomes in patients with acute ischaemic stroke after intravenous thrombolysis. QJM. 2022;115:7–11. doi: 10.1093/qjmed/hcaa253

10. Yu J, Zhang CG, Zhang SP, Xiao WM, Pan PX, Liu ZH, Chu XF, Gao QC, Xu AD, Xu ZQ, et al. Inordinate glucose variation poststroke is associated with poor neurological improvement in patients without history of diabetes. CNS Neurosci Ther. 2014;20:503–508. doi: 10.1111/cns.12251

11. Hui J, Zhang J, Mao X, Li Z, Li X, Wang F, Wang T, Yuan Q, Wang S, Pu M, et al. The initial glycemict variability is associated with early neurologi cal deterioration in diabetic patients with acute ischemic stroke. Neurol Sci. 2018;39:1571–1577. doi: 10.1007/s10072-018-3463-6

12. Cai Y, Wang C, Di W, Li W, Liu J, Zhou S. Correlation between blood glucose variability and the risk of death in patients with severe acute stroke. Rev Neurol (Paris). 2020;176:582–586. doi: 10.1016/j.neurol.2019.12.003

13. Fuentes B, Castillo J, San José B, Leira R, Serena J, Vivancos J, Dávalos A, Ñuñez AG, Egido J, Díez-Tejedor E; Stroke Project of the Cerebrovascular Diseases Study Group, Spanish Society of Neurology. The prognostic value of capillary glucose levels in acute stroke: the Glycemia in Acute Stroke (GLUAS) study. Stroke. 2009;40:562–568. doi: 10.1161/StROKEAHA.108.519926

14. Chen X, Liu Z, Miao J, Zheng W, Yang Q, Ye X, Zhuang X, Peng F. High stress hyperglycemia ratio predicts poor outcome after mechanical thrombectomy for ischemic stroke. J Stroke Cerebrovasc Dis. 2019;28:1668–1673. doi: 10.1016/j.jstrokecerebrovasdis.2019.02.022

15. Bruno A, Durlakski VL, Hall CE, Juanita R, Barsan WG, Janis S, Meurer WJ, Fanslier A, Johnston KC; SHINE Investigators. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke. 2014;9:246–251. doi: 10.1111/ijs.12045

16. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478. doi: 10.2337/dc08-0545

17. Su YW, Hsu CY, Guo YW, Chen HS. Usefulness of the plasma glucose concentration-to-HbA1c ratio in predicting clinical outcomes during acute illness with extreme hyperglycemia. Diabetes Metab. 2017;43:40–47. doi: 10.1016/0742-309X(01)00571-2

18. Umpierrez GE, Isaacs SD, Bazzanet A, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978–982. doi: 10.1210/jcem.87.3.8341

19. Kirsles J. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36:3008–3013. doi: 10.1097/CCM.0b013e3181e813b2

20. Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O’Dea H, Stranks SN, Burt MG, Dooque MP. Relative hyperglycaemia, a marker of critical illness: introducing the stress hyperglycaemia ratio. J Clin Endocrinol Metab. 2015;100:4490–4497. doi: 10.1210/jc.2015-2660

21. Wang L, Zhou Z, Tian X, Wang H, Yang D, Hao Y, Shi Z, Lin M, Wang Z, Zheng D, et al; ACTUAL Investigators. Impact of relative blood glucose changes on mortality risk of patient with acute ischemic stroke and treated with mechanical thrombectomy. J Stroke Cerebrovasc Dis. 2019;28:213–219. doi: 10.1016/j.jstrokecerebrovasdis.2018.09.036

22. Tzimolas K, Dimitriou P, Bouzina SD, Spanou M, Kostaki S, Angelopoulou SM, Papadopoulou M, Giampatits M, Savopoulou C, Hatzizilos Al. Stress hyperglycemia and acute ischemic stroke in-hospital outcome. Metabolism. 2017;67:99–105. doi: 10.1016/j.metabol.2016.11.011

23. Kim YS, Kim C, Jung KH, Kwon HM, Heo SH, Kim BJ, Kim YD, Kim JM, Lee SH. Range of glucose as a glycemic variability and 3-month outcome in diabetic patients with acute ischemic stroke. PLoS One. 2017;12:e0183894. doi: 10.1371/journal.pone.0183894

24. Chamorro A, Brown S, Amaro S, Hill MD, Murr DW, Dippel DW, van Zwam W, Butcher K, Ford GA, den Hertog HM, et al; HERMES Collaborators. Glucose modifies the effect of endovascular thrombectomy in patients with acute stroke. Stroke. 2019;50:6960–696. doi: 10.1161/STROKEAHA.118.023769

25. Bao Y, Gu D. Glycated hemoglobin as a marker for predicting outcomes of patients with stroke (Ischemic and Hemorrhagic): a systematic review and meta-analysis. Front Neurol. 2021;12:462899. doi: 10.3389/fneur.2021.642899

26. Gordon WR, Salamo RM, Behera A, Chibnall J, Alshekhlee A, Callison RC, Edgell RC. Association of blood glucose and clinical outcome after mechanical thrombectomy for ischemic stroke. J Stroke Cerebrovasc Dis. 2018;7:182–188. doi: 10.1016/j.jstrokecerebrovasdis.2019.02.022

27. Kim Y, Lee SH, Kim C, Kang MK, Yoon BW, Kim TJ, Bae JS, Lee JH. Personalized consideration of admission-glucose gap between estimated average and initial glucose levels on short-term stroke outcome. J Pers Med. 2021;11:139. doi: 10.3390/jpm11020139